International Companies

Eli Lilly issues upbeat guidance for 2026 amid solid demand for weight-loss drugs

By Michele Maatouk

Date: Wednesday 04 Feb 2026

(Sharecast News) - Eli Lilly shares surged in pre-market trade on Wednesday after the US pharmaceutical firm struck an upbeat tone on the outlook for 2026, amid growing demand for its weight loss drugs.
The company said fourth-quarter revenue rose 43% to $19.3bn, driven by volume growth from both Mounjaro and...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page